Philippe Rey
28, Rue Laennec
Lyon, 69008, France
Lyon, 69008, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen.
Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 17, 2026
Catastrophic CD34+ autologous hematopoietic stem cell collection despite sustained mobilization and solutions to rescue the harvests.
Journal: Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine
Published: May 23, 2026
Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R-MPVA) Regimen With Sequential Addition of Etoposide to R-MPV and Ifosfamide to R-AraC for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study.
Journal: Hematological oncology
Published: February 05, 2026
Individualized physical activity program for older adults undergoing chemotherapy for hematologic malignancies.
Journal: Journal of geriatric oncology
Published: October 10, 2025
Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma.
Journal: The New England journal of medicine
Published: June 03, 2025
Real-world treatment and long-term outcomes after autologous stem cell transplantation in first line for myeloma in France and Algeria before the daratumumab era.
Journal: Current research in translational medicine
Published: February 25, 2025
Detection of potential complications in cancer survivors after chemotherapy and development of a regional care network: the PASCA feasibility study.
Journal: Frontiers in medicine
Published: July 26, 2024
Impact of the total lesion glycolysis (TLG) in predicting response of follicular lymphoma to rituximab.
Journal: British journal of haematology
Published: July 13, 2024
Last Updated: 09/26/2026